China's R&D Outsourcing Market Reaches $315 Million, Expected To Maintain High Growth Through 2016
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Chinese contact research organizations are expected to expand business at a 23 percent compound annual growth rate between 2009 and 2016, while the value of the market reached $315 million in 2009, said global consulting company Frost & Sullivan in a recent report
You may also be interested in...
The Rise Of The Chinese CRO: New Models For An Emerging Player
SHANGHAI - Shrinking margins are adding pressure to contract research organizations in the U.S., and on the other side of the globe, CROs in China are facing the same problem, due to higher labor costs and appreciation of the RMB. Led by WuXi AppTec Inc., the largest Chinese CRO, local CROs are expanding services by entering into new partnering models with multinational clients and preparing for increasing domestic demands
The Rise Of The Chinese CRO: New Models For An Emerging Player
SHANGHAI - Shrinking margins are adding pressure to contract research organizations in the U.S., and on the other side of the globe, CROs in China are facing the same problem, due to higher labor costs and appreciation of the RMB. Led by WuXi AppTec Inc., the largest Chinese CRO, local CROs are expanding services by entering into new partnering models with multinational clients and preparing for increasing domestic demands
China's Second-largest CRO Seeks Initial Public Offering In The U.S.
Seeking to join top competitor WuXi PharmaTech on the New York Stock Exchange, ShangPharma, the second-largest contract research organization in China, is looking to raise an estimated $89.9 million in an initial public offering expected to debut the week of Oct. 18